News | Pharmaceuticals | December 11, 2018

Nationwide Recall of Valsartan Blood Pressure Medication Expanded

Mylan recall initiated due to trace amounts of an impurity classified as a probable human carcinogen

Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication

December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all lots of products containing Valsartan within expiry due to an impurity that has been classified as a probable human carcinogen. Valsartan is used for the treatment of high blood pressure for the treatment of heart failure, and to reduce cardiovascular mortality following myocardial infarction.

The 104 additional lots include:

  • Twenty-six (26) lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, 5mg/320mg and 10mg/320mg strengths);
  • Fifty-one (51) lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg and 320 mg strengths); and
  • Twenty-seven (27) lots of Valsartan and Hydrochlorothiazide Tablets, USP (80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg and 320mg/25mg strengths).

Valsartan in combination with amlodipine or hydrochlorothiazide is used for the treatment of high blood pressure. Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication. Patients who are on valsartan should continue taking their medication, as the risk of harm to the patient’s health may be higher if the treatment is stopped immediately without any alternative treatment.

These products are being recalled due to detected trace amounts of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Valsartan, USP, manufactured by Mylan Laboratories Ltd. NDEA is a substance that occurs naturally in certain foods, drinking water, air pollution and industrial processes, and has been classified as a probable human carcinogen according to the International Agency for Research on Cancer (IARC).

The finished products are manufactured by Mylan Pharmaceuticals Inc. and Mylan Laboratories Ltd. These batches were distributed in the U.S. between March 2017 and November 2018.   

Mylan is notifying its distributors and customers by letter and is arranging for return of all recalled products. Wholesalers, retailers and consumers that are in possession of recalled product should contact Stericycle at 1-888-406-9305 for the return of the recalled product. Normal business hours are Monday through Friday 8 a.m. to 5 p.m. EST.

Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using these drug products.

  • Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. Complete and submit the report Online: www.fda.gov/medwatch/report.htm
  • Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form or submit by fax to 1-800-FDA-0178.

The full expanded list of recalled batches can be seen here.

For more information: www.fda.gov

 

Related Content

Hypertension With Progressive Cerebral Small Vessel Disease Increases Cognitive Impairment Risk
News | Hypertension | January 08, 2019
Patients with high blood pressure and progression of periventricular white matter hyperintensities showed signs of...
Barbershop Intervention Continues to Lower Blood Pressure at One Year
News | Hypertension | December 27, 2018
African-American men participating in a blood pressure reduction program implemented in barbershops continued to have...
Analytics 4 Life and Actelion to Develop New Diagnostics for Pulmonary Hypertension
News | Hypertension | December 14, 2018
Digital health company Analytics 4 Life and Actelion Pharmaceuticals Ltd. announced a collaborative agreement to...
Hypertensive Crisis Five Times More Likely Among Blacks, according to a late-breaking study at AHA 2018. #AHA #AHA18 #AHA2018
News | Hypertension | November 13, 2018
Black adults experience dangerous spikes in high blood pressure, called a hypertensive crisis, at a rate that is five...
Home Monitoring Confirms Clinic Diagnosis of High Blood Pressure
News | Hypertension | October 29, 2018
Blood pressure readings of 130/80 millimeters of mercury (mmHg) or higher taken at home can be used to diagnose...
 Pulmonary artery denervation for CpcPH from the PADN-5 trial. #TCT2017

A series of procedural images of a pulmonary artery denervation for CpcPH from the PADN-5 trial.

News | Hypertension | October 04, 2018
October 4, 2018 — Pulmonary artery denervation (PADN) is associated with significant improvements in hemodynamic and
BackBeat Cardiac Neuromodulation Therapy Reduces Blood Pressure at Two Years
News | Hypertension | October 02, 2018
Two-year results of the Moderato I Study demonstrated immediate, substantial and sustained reduction in blood pressure...
Most Black Adults Have High Blood Pressure Before Age 55
News | Hypertension | July 30, 2018
July 30, 2018 — Approximately 75 percent of black and men women are...
American Heart Association Announces New Hypertension Center Certification
News | Hypertension | July 05, 2018
Physician practices now have access to new resources to improve their standard of quality care for hypertension...
Overlay Init